SomnoMed Limited (FRA:RJV)

SomnoMed Statistics

Total Valuation

SomnoMed has a market cap or net worth of EUR 99.59 million. The enterprise value is 94.37 million.

Market Cap	99.59M
Enterprise Value	94.37M

Important Dates

The last earnings date was Friday, November 28, 2025.

Earnings Date	Nov 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	218.18M
Shares Outstanding	n/a
Shares Change (YoY)	+75.54%
Shares Change (QoQ)	+0.79%
Owned by Insiders (%)	8.37%
Owned by Institutions (%)	26.10%
Float	113.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	61.41
PS Ratio	1.60
PB Ratio	3.85
P/TBV Ratio	4.72
P/FCF Ratio	33.27
P/OCF Ratio	22.92
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.46, with an EV/FCF ratio of 31.52.

EV / Earnings	-48.91
EV / Sales	1.50
EV / EBITDA	39.46
EV / EBIT	n/a
EV / FCF	31.52

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.17.

Current Ratio	1.51
Quick Ratio	1.10
Debt / Equity	0.17
Debt / EBITDA	1.89
Debt / FCF	1.50
Interest Coverage	-0.77

Financial Efficiency

Return on equity (ROE) is -7.56% and return on invested capital (ROIC) is -0.37%.

Return on Equity (ROE)	-7.56%
Return on Assets (ROA)	-0.26%
Return on Invested Capital (ROIC)	-0.37%
Return on Capital Employed (ROCE)	-0.59%
Revenue Per Employee	207,470
Profits Per Employee	-6,432
Employee Count	300
Asset Turnover	1.48
Inventory Turnover	6.53

Taxes

In the past 12 months, SomnoMed has paid 1.50 million in taxes.

Income Tax	1.50M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +94.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+94.55%
50-Day Moving Average	0.45
200-Day Moving Average	0.37
Relative Strength Index (RSI)	50.86
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SomnoMed had revenue of EUR 62.24 million and -1.93 million in losses. Loss per share was -0.01.

Revenue	62.24M
Gross Profit	37.25M
Operating Income	-173,622
Pretax Income	-426,427
Net Income	-1.93M
EBITDA	883,962
EBIT	-173,622
Loss Per Share	-0.01

Balance Sheet

The company has 9.65 million in cash and 4.48 million in debt, giving a net cash position of 5.17 million.

Cash & Cash Equivalents	9.65M
Total Debt	4.48M
Net Cash	5.17M
Net Cash Per Share	n/a
Equity (Book Value)	25.90M
Book Value Per Share	0.12
Working Capital	8.13M

Cash Flow

In the last 12 months, operating cash flow was 4.35 million and capital expenditures -1.35 million, giving a free cash flow of 2.99 million.

Operating Cash Flow	4.35M
Capital Expenditures	-1.35M
Free Cash Flow	2.99M
FCF Per Share	n/a

Margins

Gross margin is 59.85%, with operating and profit margins of -0.28% and -3.10%.

Gross Margin	59.85%
Operating Margin	-0.28%
Pretax Margin	-0.69%
Profit Margin	-3.10%
EBITDA Margin	1.42%
EBIT Margin	-0.28%
FCF Margin	4.81%

Dividends & Yields

SomnoMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-75.54%
Shareholder Yield	-75.54%
Earnings Yield	-1.94%
FCF Yield	3.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SomnoMed has an Altman Z-Score of 1.99 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.99
Piotroski F-Score	4